CN114917176A - Compound probiotics capable of improving ozostomia - Google Patents

Compound probiotics capable of improving ozostomia Download PDF

Info

Publication number
CN114917176A
CN114917176A CN202210245149.0A CN202210245149A CN114917176A CN 114917176 A CN114917176 A CN 114917176A CN 202210245149 A CN202210245149 A CN 202210245149A CN 114917176 A CN114917176 A CN 114917176A
Authority
CN
China
Prior art keywords
cells
lactobacillus plantarum
lactobacillus
ccfm1214
ccfm1215
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210245149.0A
Other languages
Chinese (zh)
Other versions
CN114917176B (en
Inventor
崔树茂
张秋香
蒋震涛
毛丙永
唐鑫
陆文伟
赵建新
陈卫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangnan University
Original Assignee
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangnan University filed Critical Jiangnan University
Priority to CN202210245149.0A priority Critical patent/CN114917176B/en
Publication of CN114917176A publication Critical patent/CN114917176A/en
Application granted granted Critical
Publication of CN114917176B publication Critical patent/CN114917176B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a compound probiotic for improving halitosis, belonging to the technical field of microorganisms. The Lactobacillus plantarum complex is a composition of Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 cells and/or extracellular metabolites thereof and Lactobacillus salivarius CCFM1215 cells and/or extracellular metabolites thereof. The composition has effects of inhibiting production of VSCs by Fusobacterium nucleatum, and relieving halitosis in vivo, and has effect in lowering halitosis value by 63.37% at 28 th day.

Description

Compound probiotics capable of improving ozostomia
Technical Field
The invention relates to a composite probiotic for improving halitosis, in particular to a composite probiotic consisting of lactobacillus plantarum and lactobacillus salivarius for improving halitosis caused by fusobacterium nucleatum, belonging to the technical field of microorganisms.
Background
Halitosis, the third major oral health problem, afflicts many people. 80% -90% of the bad breath is associated with oral factors, called halitosis of oral origin. The main constituents of the breath are Volatile Sulfur Compounds (VSCs), 90% of which are hydrogen sulfide and methyl mercaptan, and also dimethyl sulfide, etc. The cause of odor is that microorganisms in the oral cavity decompose sulfur-containing amino acids (cystine, cysteine, methionine) or serum to produce metabolites. The bacteria producing VSCs are mainly fusobacterium nucleatum, porphyromonas gingivalis, prevotella intermedia, Solobacterium moorei, and the like.
At present, chemotherapy exists in treatment methods, such as treatment of halitosis by using chlorhexidine, essential oil and other mouthwash products, but the methods are poor in mildness and safety, and the essential oil only can cover odor, so that the concentration of VSCs is not reduced substantially, and the treatment is temporary and permanent, so the effect is poor; the traditional Chinese medicine has slow and general effect. For halitosis caused by microorganisms, the problem caused by microorganisms is solved by 'taking medicines according to symptoms'. At present, probiotics are gradually applied to the oral cavity field due to the characteristics of safety and mildness.
For a method of improving halitosis using probiotics, US2006171901 discloses a streptococcus salivarius able to inhibit anaerobic bacteria; CN201811441014.1 adds dendrobe oligomannose as the prebiotics component, adds multiple probiotic components, aims at designing a fresh breath solid beverage, but does not have the effect evaluation of improving breath. CN109045071A discloses a composition for alleviating halitosis for treating halitosis of stomach origin, which comprises 7 kinds of probiotics and green tea powder, etc.; CN201910453030.0 evaluated an instant improvement effect on the breath of volunteers after gargling the compound probiotic buccal tablet for 3min, but no evaluation was made on a long-term effect of taking the compound probiotic buccal tablet; CN201810931190.7 aims at such as Helicobacter pylori (Helicobacter pylori) to invent a probiotic composition for improving halitosis status, and the composition relates to 7 kinds of lactobacillus, and has high cost. CN111235063A discloses dry oral probiotic powder for use in oral care products to improve oral micro-ecology, effective in reducing biofilm of streptococcus mutans, said oral probiotic comprising lactobacillus plantarum XY-381, lactobacillus paracasei XY-256, and lactobacillus salivarius XY-101, but reducing biofilm in vitro is not necessarily effective in vivo and not necessarily long lasting.
Disclosure of Invention
[ problem ] to
In the prior art, most of probiotics capable of relieving halitosis are targeted by bacteriostasis, and in many cases, in-vivo verification experiments are not available, or only effect evaluation in a short time is available.
[ solution ]
The invention provides a lactobacillus complex capable of reducing Volatile Sulfides (VSCs) produced by fusobacterium nucleatum, and has the effect of improving halitosis in vivo.
The Lactobacillus plantarum is Lactobacillus plantarum (Lactobacillus plantarum)) CCFM1214 cells and/or extracellular metabolites thereof, and Lactobacillus salivarius CCFM1215 cells and/or extracellular metabolites thereof. The Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 has the capacity of inhibiting Fusobacterium nucleatum in vitro and the function of relieving halitosis in vivo, specifically, (1) culture supernatant of the CCFM1214 can prevent the formation of a Fusobacterium nucleatum biofilm, and when the addition amount is 10%, the inhibition rate reaches 68.61%; (2) the growth of the fusobacterium nucleatum is inhibited to a certain extent; (3) has good copolymerization capacity with fusobacterium nucleatum; (3) can inhibit the production of H by Fusobacterium nucleatum 2 Expression of the gene Fn1220 of S; (4) can improve the breath value of volunteers, and the VSCs value is reduced by 44.29%. The Lactobacillus salivarius CCFM1215 has the capacity of inhibiting fusobacterium nucleatum in vitro and has the function of relieving halitosis in vivo, specifically, (1) the culture supernatant of the CCFM1215 can prevent the formation of a fusobacterium nucleatum biofilm, and when the addition amount is 10%, the inhibition rate can reach 71.07%; (2) the growth of the fusobacterium nucleatum is inhibited to a certain extent; (3) has good copolymerization ability with fusobacterium nucleatum; (4) can inhibit the production of H by Fusobacterium nucleatum 2 Expression of the gene Fn1220 of S; (5) can improve the breath value of volunteers, and the VSCs value is reduced by 46.50%.
In the lactobacillus plantarum complex, the ratio of lactobacillus plantarum to lactobacillus salivarius is 1: 1.
The bacterial colonies of the Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 and the Lactobacillus salivarius CCFM1215 on the MRS culture medium are smooth, white and round small bulges.
The invention also provides a product for improving halitosis, which comprises the live cells or dead cells or extracellular metabolites of the Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 and the live cells or dead cells or extracellular metabolites of the Lactobacillus salivarius CCFM 1215. The dead cells include, but are not limited to, naturally inactivated cells or cells after inactivation. The product forms include, but are not limited to, microbial preparations, solid beverages, breath fresheners, toothpastes, mouthwashes.
[ advantageous effects ]
The Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 and the Lactobacillus salivarius CCFM1215 obtained by screening have the capacity of inhibiting the production of VSCs by Fusobacterium nucleatum in vitro, and the combination of the Lactobacillus plantarum CCFM1214 and the Lactobacillus salivarius CCFM1215 in vivo has the function of relieving halitosis, and is specifically shown in the following steps: can improve the breath value of volunteers, and can reduce the breath value by 63.37% at 28 days.
Biological material preservation
The Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 is preserved in Guangdong province microbial strain preservation center at 12-17 th 2021 with the preservation address of No. 59-5 th lough of Michelia Tokyo No. 100, Guangzhou city, and the preservation number is GDMCC No. 62140.
Lactobacillus salivarius CCFM1215 (Lactobacillus salivarius) is preserved in Guangdong province microbial strain collection center at 12-17 th 2021, with the preservation address of No. 59, No. 5, Michelia furiosaefolia No. 100, Michelia furiosaefolia, Guangzhou, and the preservation number is GDMCC No. 62141.
Drawings
FIG. 1: crowd experiment flow chart
Detailed Description
The media involved in the following examples are as follows:
MRS culture medium: 5.0g/L yeast powder, 10.0g/L beef extract, 10.0g/L peptone, 20.0g/L glucose, 2.0g/L anhydrous sodium acetate, 2.0g/L hydrogencitrate diamine, 2.6g/L dipotassium hydrogen phosphate, 0.25g/L manganese sulfate monohydrate, 0.5g/L magnesium sulfate heptahydrate, Tween-801 mL/L and pH of 6.2-6.4.
Food grade MRS medium (/ L): 10g of food-grade yeast extract (from Angel Yeast Co., Ltd.), 20g of food-grade glucose (from Shanghai-Hai-Capro Biotechnology Co., Ltd.), 10g of soybean peptone (from Tenbang chemical technology Co., Ltd.), 0.1g of food-grade magnesium sulfate (from Laiyu chemical Co., Ltd., Rizhou), 0.05g of food-grade manganese sulfate (from food blending Co., Ling Yun-Gao-Tou-Teh Co., Ltd.), 5g of food-grade sodium acetate (from Jiangsu-Kelun Multi food blending Co., Ltd.), 2g of food-grade ammonium citrate (from Jiangsu-Kelun-Dun food blending Co., Ltd.), and 2g of food-grade dipotassium hydrogen phosphate (from Xufeng-Rui biological technology Co., Ltd.)
BHI medium: purchased from Qingdao Haibo, and additionally added with 0.05 percent of hemin and 0.1 percent of vitamin K1, and the pH value is 7.2-7.4.
The bacterial suspensions referred to in the following examples were prepared as follows:
lactobacillus supernatant: inoculating in MRS liquid culture medium at 1% inoculum size, culturing at 37 deg.C for 24 hr, centrifuging at 4 deg.C for 10min at 10,000r/min, filtering with 0.22 μm filter membrane for sterilization, storing at 4 deg.C for short period, and storing at-20 deg.C for long period.
The Lactobacillus plantarum CCFM1214 in the following examples was selected from cabbage, and the yield of clostridium nucleatum-inhibiting VSCs was used as an index for screening, and was identified as Lactobacillus plantarum (Lactobacillus plantarum).
The Lactobacillus salivarius CCFM1215 used in the following examples was screened in feces and identified as Lactobacillus salivarius by using the production of the C.nucleatum-inhibiting VSCs as an index.
Example 1: effect of CCFM1214 and CCFM1215 on production of VSCs by Fusobacterium nucleatum
Control (Control group): will 10 7 CFU/mL of Fusobacterium nucleatum suspension 1700. mu.L and 300. mu.L of MRS medium were added to Hungaret tubes and co-cultured for 9 h. Since the upper limit of the Halimeter detection is 2000, the control group was calculated after gas dilution. Inserting 2 50mL syringe needles into a test tube, connecting one end of the test tube with a Halimeter halitosis instrument, balancing air pressure while oscillating by an oscillator, after oscillating and mixing uniformly, sucking 1mL of air by a 1mL syringe, immediately adding the air into an empty Hencatel test tube, and measuring while oscillating.
CCFM1214 or CCFM 1215: will 10 7 CFU/mL fusobacterium nucleatum suspension 1700. mu.L and lactobacillus supernatant 300. mu.L were added to Hencatel tube in 2mL, co-cultured for 9h, and inserted into the tube with 2 50mL syringe needles, one end connected to Halimeter halitosis instrument, one end for balancing air pressure and the other end for measuring with oscillator.
CCFM1214+ CCFM 1215: will 10 7 CFU/mL fusobacterium nucleatum suspension 1700. mu.L and C150. mu.L2mL of the supernatant of CFM1214 and 150. mu.L of CCFM1215 were added to Henkett tubes and incubated for 9h, and 2 50mL syringe needles were inserted into the tubes, one end of which was connected to a Halimeter halitosis meter, one end of which was used to balance the air pressure and the other end was shaken with a shaker.
As shown in Table 1, the inhibition ratio of VSCs produced by F.nucleatum was 93.28% when the two bacteria were combined, which is superior to the effect of the single bacteria.
TABLE 1 influence of CCFM1214 and CCFM1215 pairs on VSCs production by Fusobacterium nucleatum
Figure RE-GDA0003748310410000041
Example 2: preparation of probiotic bacteria powder
Bacterial sludge: culturing Lactobacillus plantarum CCFM1214 and Lactobacillus salivarius CCFM1215 in food-grade MRS culture medium at 37 deg.C for 24h, centrifuging, discarding supernatant, collecting bacterial sludge, washing with sterile water, centrifuging, discarding supernatant, and collecting bacterial sludge.
Freeze-drying protective agent: 200g/L of skim milk powder and 300g/L of mannitol. The ratio of the bacterial sludge to the freeze-drying protective agent is 1: 3.
Freeze-drying: uniformly mixing the bacterial sludge and the protective agent, precooling overnight at-80 ℃, and freeze-drying in a freeze-dryer.
CCFM1214 bacterial powder: mixing lyophilized bacterial powder with fructo-oligosaccharide to give a content of 10 g/g 9 And (5) packaging CFU/g viable bacteria, wherein each bag of the bacteria powder is 2 g. CCFM1215 bacterial powder: mixing lyophilized bacterial powder with fructo-oligosaccharide to give a content of 10 g/g 9 CFU/g viable bacteria, and packaging, wherein each bag of the bacterial powder is 2 g. Compounding bacterial powder: mixing lyophilized 2 kinds of bacteria powder with fructo-oligosaccharide to obtain a mixture containing 10 per gram of bacteria powder 9 CFU/g CCFM1214 and 10 9 CFU/g CCFM1215 viable bacteria. And (5) packaging, wherein each bag of the fungus powder is 2 g.
Example 3: population experiment for improving halitosis by using probiotic powder
Volunteer recruitment and experimental process
Inclusion criteria for volunteer recruitment: halimeter test value is more than 200ppb, and antibiotics are not used within 1 month; exclusion criteria: smoking, in pregnancy.
66 volunteers were recruited and randomly divided into 4 groups, 15 placebo groups, 15 CCFM1214 bacteria powder groups, 15 CCFM1215 bacteria powder groups, 21 composite bacteria powder groups, and the flow and period of the experiment are shown in FIG. 1. The experiment was carried out for a total of 5 weeks, 4 weeks with a bag of fungal powder (placebo) 30min after meal, 1 week with no fungal powder (placebo). The breath test was performed by using a Halimeter halitosis instrument on days 1, 7, 14, 28 and 35 from the first day of taking the bacterial powder, wherein oral health tests including a dental Calculus Index (CI), a plaque index (PLI), a Gingival Index (GI) and a Gingival Bleeding Index (GBI) were performed by doctors on the baseline and the 28 th days, and the test results are shown in table 3.
Second, detection method
1. Detection by a Halimeter halitosis instrument: the volunteers were asked to fast and stop water for 2h before examination, and before sampling, the subjects were closed for 3min, and the end of the suction tube was inserted into the mouth of the patient to a depth of about 2.5cm, the lips should be almost closed, and a little space was allowed between the lips and the suction tube, so that the lips and the teeth could not be pressed against the suction tube. During sampling, breathing should be performed through the nose. When the instrument panel value increased to a stable maximum and began to decrease, the maximum was recorded and the average was taken over three tests, the results are shown in table 2.
TABLE 2 volunteers before and after taking the fungus powder change in breath value (ppb)
Figure RE-GDA0003748310410000051
Note: probiotic group compared to baseline period, p<0.05，**p<0.01，***p<0.001， # Placebo group compared to baseline period, p<0.05
2. Oral health examination: the diagnosis was performed by a specialist and the results are shown in Table 3.
Dental calculus index: 0 is no soft calculus or dental calculus. 1, a little soft calculus or tartar, but not more than l/3 of the tooth surface. 2, there is calculus, 1/3 which does not exceed the coronal plane, and there is a small amount of subgingival calculus. 3, the calculus does not exceed 2/3 of the crown surface, and more subgingival calculus exists.
Plaque index: 0 ═ no plaque in the gingival margin; 1, the tooth surface of the gingival margin area has thin bacterial plaque, but the bacterial plaque can not be seen by visual inspection, and the bacterial plaque can be scraped out by using the side surface of a probing tip; 2, the moderate and equivalent bacterial plaque can be seen at the gingival margin or the adjacent surface; 3, a large amount of soft scale exists in the gingival sulcus or in the gingival margin area and the adjacent surface.
Gum index: 0 ═ gum health; 1 ═ gingival mild inflammation: the color of the gum is slightly changed, the gum is slightly edematous, and bleeding is avoided during probing; 2 ═ moderate inflammation of the gums: the gum is red, the edema is bright, and bleeding is detected; 3 ═ gingival severe inflammation: the gums are markedly inflamed or ulcerated and have a tendency to bleed spontaneously.
Gingival bleeding index: 0 ═ gum health, no inflammation and bleeding; 1, the color of the gum changes with inflammation, and bleeding does not occur after probing; 2, after probing, bleeding with a bit; bleeding after probing is linear along the gingival margin; 4, bleeding is full and overflows the gingival sulcus; 5 automatic bleeding.
TABLE 3 volunteer oral health examination changes
Figure RE-GDA0003748310410000061
Note: p <0.05 in probiotic group compared to baseline
3. Results of the experiment
During the baseline period, the mouth odor values of the placebo group and the composite powder group are not significantly different, and when the composite powder is taken for 1 week, the mouth odor value of the composite powder group is significantly reduced (p <0.01), 46.89% is reduced, 40.67% is reduced by CCFM1214 group, 43.69% is reduced by CCFM1215 group, and the mouth odor value of the placebo group is not significantly changed. After two weeks of administration, the oral cavity gas value of the composite bacterial powder group is reduced extremely remarkably (p is less than 0.001), and the two single strains are reduced remarkably (p is less than 0.01). The placebo group also had a significant reduction (p <0.05), probably due to psychological effects, as breath was also physiologically and psychologically affected, but the reduction was transient and returned to the original value during the washout period. The whole compound fungus powder group is in a descending trend, the breath value is slightly increased after the fungus powder is not taken, but the effect is still very obvious (p is less than 0.001). After the bacterial powder is taken for 28 days, the breath value of the composite bacterial powder group is reduced by 63.37%, the breath value of the CCFM1214 bacterial powder group is 44.29%, and the breath value of the CCFM1215 bacterial powder group is 46.50%. Overall, the effect of the complex bacteria was considered superior to that of the individual bacteria, and the subsequent further analysis of the effect of the probiotic on the oral health was performed.
The oral health status of the composite bacterial powder group is well changed overall, particularly the gingival index is remarkably improved (p is less than 0.05), while the oral status of the placebo group is not remarkably improved.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by one skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (10)

1. Use of probiotic bacteria in a product for alleviating oral malodor, characterized in that the Lactobacillus plantarum complex is a composition of Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 cells and/or extracellular metabolites thereof, and Lactobacillus salivarius CCFM1215 cells and/or extracellular metabolites thereof;
the Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 is preserved in Guangdong province microbial strain preservation center at 12-17 th 2021 with the preservation address of No. 59-5 th lough of Michelia Tokyo No. 100, Guangzhou city, and the preservation number is GDMCC No. 62140.
Lactobacillus salivarius CCFM1215 (Lactobacillus salivarius) is preserved in Guangdong province microbial strain preservation center at 12-17 2021, wherein the preservation address is No. 59-5 Lou of Michelia Tokyo No. 100, Michelia Tokyo, Guangzhou city, and the preservation number is GDMCC No. 62141.
2. Use according to claim 1, wherein the Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 cells or Lactobacillus salivarius CCFM1215 cells are living or dead cells.
3. Use according to claim 1, characterized in that the product comprises: microbial preparation, solid beverage, breath freshener, toothpaste, and collutory.
4. The use according to claim 1, wherein the extracellular metabolite is obtained by culturing cells in MRS medium, centrifuging the cells, and filtering the supernatant obtained by centrifugation to remove the cells.
5. The use of any one of claims 1 to 4, wherein the dead cells include, but are not limited to, naturally inactivated cells or cells after inactivation.
6. A complex probiotic product for alleviating halitosis, characterized in that the complex Lactobacillus is a composition of Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 and/or an extracellular metabolite thereof, and Lactobacillus salivarius CCFM1215 and/or an extracellular metabolite thereof;
the Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 is preserved in Guangdong province microbial strain preservation center at 12-17 th 2021 with the preservation address of No. 59-5 th lough of Michelia Tokyo No. 100, Guangzhou city, and the preservation number is GDMCC No. 62140.
Lactobacillus salivarius CCFM1215 (Lactobacillus salivarius) is preserved in Guangdong province microbial strain preservation center at 12-17 2021, wherein the preservation address is No. 59-5 Lou of Michelia Tokyo No. 100, Michelia Tokyo, Guangzhou city, and the preservation number is GDMCC No. 62141.
7. The product according to claim 6, wherein the Lactobacillus plantarum (Lactobacillus plantarum) CCFM1214 cells or Lactobacillus salivarius CCFM1215 cells are living or dead cells.
8. The product according to claim 1, characterized in that it comprises: microbial preparation, solid beverage, breath freshener, toothpaste, and collutory.
9. The product according to claim 1, wherein the extracellular metabolite is produced by culturing the bacterial cells in MRS medium, centrifuging the culture, and filtering the supernatant obtained by centrifugation to remove the bacterial cells.
10. A product according to any one of claims 1 to 4, wherein the dead cells include, but are not limited to, naturally inactivated cells or cells after inactivation.
CN202210245149.0A 2022-03-14 2022-03-14 Composite probiotics for improving halitosis Active CN114917176B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210245149.0A CN114917176B (en) 2022-03-14 2022-03-14 Composite probiotics for improving halitosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210245149.0A CN114917176B (en) 2022-03-14 2022-03-14 Composite probiotics for improving halitosis

Publications (2)

Publication Number Publication Date
CN114917176A true CN114917176A (en) 2022-08-19
CN114917176B CN114917176B (en) 2023-06-13

Family

ID=82805114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210245149.0A Active CN114917176B (en) 2022-03-14 2022-03-14 Composite probiotics for improving halitosis

Country Status (1)

Country Link
CN (1) CN114917176B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110063374A (en) * 2019-05-28 2019-07-30 北京科拓恒通生物技术股份有限公司 A kind of compound probiotic composition for improving implication, lozenge and preparation method thereof
CN110713960A (en) * 2019-12-03 2020-01-21 嘉兴益诺康生物科技有限公司 Lactobacillus plantarum LN66 and application thereof in product for reducing halitosis risk
CN111334448A (en) * 2018-12-19 2020-06-26 扬州臻微生物技术有限公司 Preparation process of oral probiotic freeze-dried powder
US20200306325A1 (en) * 2019-03-06 2020-10-01 Oralta, Inc. Probiotic consortia for oral health
CN113005055A (en) * 2021-02-08 2021-06-22 无限极（中国）有限公司 Lactobacillus plantarum for preventing and/or treating periodontitis, culture thereof, and preparation and application thereof
CN114164157A (en) * 2022-02-09 2022-03-11 中科宜康（北京）生物科技有限公司 Lactobacillus salivarius strain ZK-88 for inhibiting inflammation, relieving swelling and aching of gum, and improving oral flora balance

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111334448A (en) * 2018-12-19 2020-06-26 扬州臻微生物技术有限公司 Preparation process of oral probiotic freeze-dried powder
US20200306325A1 (en) * 2019-03-06 2020-10-01 Oralta, Inc. Probiotic consortia for oral health
CN110063374A (en) * 2019-05-28 2019-07-30 北京科拓恒通生物技术股份有限公司 A kind of compound probiotic composition for improving implication, lozenge and preparation method thereof
CN110713960A (en) * 2019-12-03 2020-01-21 嘉兴益诺康生物科技有限公司 Lactobacillus plantarum LN66 and application thereof in product for reducing halitosis risk
CN113005055A (en) * 2021-02-08 2021-06-22 无限极（中国）有限公司 Lactobacillus plantarum for preventing and/or treating periodontitis, culture thereof, and preparation and application thereof
CN114164157A (en) * 2022-02-09 2022-03-11 中科宜康（北京）生物科技有限公司 Lactobacillus salivarius strain ZK-88 for inhibiting inflammation, relieving swelling and aching of gum, and improving oral flora balance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAO SUZUKI等: "Lactobacillus salivarius WB21-containing tablets for the treatment of oral malodor:a double-blind,randomized,pla-cebo-controlled crossover trial", 《ORAL SURG ORAL MED ORAL PATHOL ORAL RADIOL》 *

Also Published As

Publication number Publication date
CN114917176B (en) 2023-06-13

Similar Documents

Publication Publication Date Title
EP1498039B1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
AU2012293231B2 (en) Prophylactic or therapeutic agent for oral diseases
Kneist et al. Diversity of Lactobacillus species in deep carious lesions of primary molars
Spratt et al. Biofilms and the oral cavity
CN113144002B (en) Probiotic composition for maintaining oral health and application thereof
CN110257297A (en) Lactobacillus paracasei PC-01 and its application for being used to promote oral health of one plant of separation
US20060045870A1 (en) Lactic acid bacteria inhibiting halitosis
Massler et al. Fetor ex ore: a review
Achmad et al. Streptococcus colonial growth of dental plaque inhibition using flavonoid extract of ants nest (Myrmecodia pendans): An in vitro study
Johansson et al. Effects of mouthrinses with linseed extract Salinum® without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double‐blind crossover investigation
CN113957006A (en) Lactobacillus plantarum N13 and application thereof in preventing or treating dental caries and periodontitis
CN111000874A (en) Lactobacillus plantarum with dental caries prevention and treatment effect
CN111518713B (en) Lactobacillus rhamnosus capable of preventing and/or treating dental caries and application thereof
Theilade et al. Microbiological studies of plaque in artificial fissures implanted in human teeth
CN114149939B (en) Probiotic composition capable of relieving dental caries and application thereof
KR20210110163A (en) Ingestible Tablet or Powder Type Oral Cleaning Composition
Achmad et al. Analysis of Ascorbic Acid in Gingival Handling of Children's Mouth Cavity.
CN114917176B (en) Composite probiotics for improving halitosis
Scully Cancers of the oral mucosa
CN114606164B (en) Lactobacillus paracasei Probio-01 and application thereof in preparation of probiotic oral preparation
CN113046258B (en) Lactobacillus rhamnosus capable of preventing and/or treating periodontitis and application thereof
CN114621895B (en) Saliva-associated lactobacillus capable of inhibiting clostridium nucleatum and improving breath
CN114703092B (en) Lactobacillus plantarum capable of inhibiting clostridium nucleatum and improving breath
JP2006328052A (en) Composition for disinfecting porphyromonas gingivalis
CN116904341A (en) Lactobacillus rhamnosus capable of improving oral health and probiotic composition thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant